In 454 paired-end sequencing analysis (3, 8, or 20kb), has anyone found that the sequence on the left of the linker to be significantly shorter than the sequence on the right? Theoretically, a randomly sheared sample should generate reads with sequences of equal length, on average, on either side of the linker. However, I am seeing a bias for the linker to be located near the start of the read. Could the circular products be more prone to shearing at a site closer to the left side of the linker?
-
-
Your post made me check, but both for the two smaller datasets (bacterial genome 3kb old GS FLX and Titanium 8kb PE), and the larger one (eukaryotic genome Titanium 3kb, 8kb, 20kb) I don't see a significant difference between the length distributions of the left half and the right half.
Also, when I plot the position of the linker (I take the start position of the right half from the 454TrimStatus.txt as a proxy) and divide it by the original trimmed read length, there is no bias either... -
Thanks for checking! I'm curious, how are you shearing after circularization? Covaris or nebulization? Also, are you using carrier DNA? It shouldn't make a difference, I just want to rule anything put...Comment
-
In solexa sequencing, pair end library especially index PE, we also found that pollution of read1 adpter >>read2, i don‘t understand why?Comment
-
BTW, index mate pair library !Comment
-
We follow the standard protocols, so nebulization and carrier DNA.Originally posted by lzembek View PostComment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment